Inovio (INO) – INO-3107, RRP and the long road into the 2026 PDUFA

News of the day – December 29, 2025

FDA accepts INO-3107 BLA, Standard Review, PDUFA October 30, 2026

On December 29, 2025 the FDA accepted Inovio’s Biologics License Application for INO-3107 as a potential treatment for adults with Recurrent Respiratory Papillomatosis (RRP). The review classification is Standard and the agency set a PDUFA target action date of October 30, 2026. The FDA also indicated that it is currently not planning to hold an Advisory Committee for this dossier.

Inovio filed under the accelerated approval pathway, but in the file-acceptance letter the FDA flagged as a potential review issue its preliminary view that the company has not yet submitted adequate information to justify accelerated approval. Inovio still believes INO-3107 provides a meaningful benefit over surgery and plans to request a meeting with the agency to discuss how to remain eligible for the accelerated route. For now, the company explicitly says it is not preparing a traditional-pathway filing.

Equity market reaction was brutal: on the same day, INO shares dropped about 24% to 1.73 USD, with volume (about 6.1 million shares) far above the recent average, underscoring how central this BLA is to the entire equity story.

Company and DNA medicines platform

Inovio is a small biotechnology company focused on DNA medicines – plasmid-based constructs delivered with the proprietary CELLECTRA electroporation device. The idea is to let host cells transiently produce antigenic proteins or therapeutic antibodies directly in vivo, avoiding some of the limitations of viral vectors and classic protein manufacturing.

The current pipeline is concentrated around three thematic pillars:

• HPV-related diseases: INO-3107 for adult RRP, and the VGX-3100 / INO-3100 family for cervical and lower-genital tract lesions (now largely de-prioritised outside China).
• Immuno-oncology: multi-antigen candidates such as INO-5401 for glioblastoma and prevention programmes in BRCA-mutated populations, often in combination with checkpoint inhibitors.
• Infectious diseases and DMAb: Ebola booster INO-4201 and DNA-encoded monoclonal antibodies (DMAb) in collaboration with Wistar, AstraZeneca and academic centres.

From a value-creation standpoint, however, the entire near-term equity story is dominated by INO-3107 in adult RRP.

INO-3107 in RRP – mechanism, data and designations

Mechanism and target disease

INO-3107 is a DNA immunotherapy designed to induce T-cell responses against the E6 and E7 proteins of HPV-6 and HPV-11, the low-risk HPV types responsible for most cases of RRP. The idea is to train cytotoxic T cells to recognise and clear infected cells in the respiratory tract, reducing or even eliminating the papillomas that currently require repetitive surgery.

RRP itself is a rare but debilitating airway disease. Benign papillomas grow in the larynx and sometimes the lower airway, causing hoarseness, airway obstruction, repeated surgical interventions and a meaningful impact on quality of life. Surgery remains the standard of care but is palliative and damaging over time.

Phase 1/2 and long-term follow-up

The pivotal clinical package rests on:

• a Phase 1/2 open-label trial (RRP-001) in 32 adults who had at least two surgeries in the year before dosing; and
• a retrospective long-term follow-up (RRP-002) in 28 of those patients, with a median total follow-up of about 2.8 years after treatment.

Key reported points from the Phase 1/2 and retrospective dataset:

• Patients had a median of 4 surgeries (range 2–8) in the 12 months prior to INO-3107.
• In the first 12 months after dosing, around 72% of patients achieved a 50–100% reduction in the number of surgeries.
• In the second 12-month period, without any additional dosing, the proportion with a 50–100% reduction increased to about 86%, with the complete response rate (zero surgeries) rising from roughly 28% to 50%.
• The mean number of surgeries per year dropped from about 4.1 in the pre-treatment period to 1.7 in Year 1 and 0.9 in Year 2, with partial data into Year 3 maintaining the downward trend.
• Safety has been benign so far, with mostly low-grade adverse events such as injection-site pain and fatigue and no significant long-term safety signal reported in the RRP cohorts.

Immunology work published in peer-reviewed journals shows that INO-3107 induces antigen-specific CD4 and CD8 T-cells that traffic to airway tissue and correlate with clinical improvement, giving mechanistic support to the observed reduction in surgeries.

Regulatory status and designations

On the regulatory front, INO-3107 has accumulated an unusually rich set of designations:

• Orphan Drug and Breakthrough Therapy designation in the United States.
• Orphan designation in the European Union.
• Innovation Passport in the UK under the ILAP framework.
• CE-mark for the CELLECTRA delivery device, allowing commercial use of the device in CE-recognising markets.

The key new piece is the BLA acceptance under Standard Review with PDUFA on 30 October 2026. The controversy around accelerated approval is now explicit: the FDA has told the company that, in its preliminary view, the current package does not yet sufficiently justify accelerated approval, even if the agency is proceeding with the review.

Inovio intends to meet the FDA to argue its case; in parallel, a confirmatory trial in adult RRP (approximately 100 patients, randomised 2:1, around 20 US sites) is planned during the review period.

Other pipeline assets (short overview)

INO-3112 – HPV-related head and neck cancer

INO-3112 combines an HPV16/18 DNA immunotherapy with the anti-PD-1 antibody LOQTORZI in high-risk, HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). The Phase 3 design has been discussed with the FDA and alignment with European regulators is in progress. This is a medium-term catalyst and unlikely to change the 2026 funding picture before INO-3107’s PDUFA.

INO-5401 – glioblastoma and BRCA-mutated prevention

INO-5401 is a three-antigen construct (hTERT, WT-1, PSMA) in early-stage development. Combination studies with Libtayo in glioblastoma have produced encouraging but non-definitive survival data; additional work in BRCA1/2-mutated subjects focuses on prevention and immune priming. These programmes are currently scientific upside rather than financial drivers.

INO-4201 and DMAb technology

INO-4201 is an Ebola booster candidate for individuals previously vaccinated with Ervebo, with early-stage data indicating robust boosting of protective immunity. The DMAb platform (DNA-encoded antibodies) has delivered proof-of-concept in humans for long-acting expression of neutralising antibodies against SARS-CoV-2, in partnership with Wistar, AstraZeneca and academic groups. These platforms are valuable scientifically, but they sit behind INO-3107 in the queue for capital and commercial attention.

Financial snapshot and five-year dilution pattern

Current financial position

• Cash, cash equivalents and short-term investments: 50.8 million USD as of 30 September 2025.
• No debt reported on the balance sheet at that date.
• Net loss Q3 2025: 45.5 million USD, roughly double the prior-year quarter, largely due to a non-cash loss on warrant revaluation; operating loss was about 21.2 million USD.
• Cash runway guidance: into the second quarter of 2026, assuming no additional financings and an estimated net cash burn of about 22 million USD in Q4 2025.

Equity raises – the pattern

Over the last five years Inovio has repeatedly issued new equity and warrants to fund operations. A non-exhaustive list of larger deals illustrates the pattern:

• January 2021 – public offering of common stock, followed by full exercise of the underwriters’ option, resulting in proceeds around the mid-hundreds of millions of dollars and a significant expansion of the share count.
• April 2024 – underwritten offering of common stock and pre-funded warrants, with expected gross proceeds of about 36 million USD; the stock fell more than 20% in after-hours trading on the news.
• December 2024 – public offering of common stock and warrants targeting about 30 million USD of gross proceeds.
• July 2025 – additional public offering combining shares and warrants, publicly announced at roughly 25 million USD in gross proceeds.
• November 2025 – underwritten stock offering of 13.158 million shares at 1.90 USD per share, plus a 30-day option for almost 2 million extra shares, again for about 25 million USD in gross proceeds.

Together with previous years’ activity, these transactions explain why many long-time retail investors describe the stock as having been turned into a “cash machine” for the company. From a purely factual standpoint, Inovio has funded essentially all of its RRP development and BLA work via repeated equity issuance, and the runway still stops well before the 2026 PDUFA date.

Retail sentiment and community chatter

Stocktwits and trading communities

On Stocktwits, INO has more than ninety-thousand followers and behaves like a classic high-beta event-driven small cap. In bullish phases the stream fills with posts focusing on “first DNA medicine”, “RRP game changer” and implied multi-bagger scenarios if INO-3107 is approved. On days like 29 December 2025, the tone flips quickly to anger and capitulation as another regulatory nuance or capital raise hits the tape.

Reddit: two very different angles

• In r/Inovio and similar spaces, some users still share optimistic breakdowns of RRP data and 2025/2026 milestones, arguing that slower-than-expected surgery counts and durable responses put the company in a strong negotiating position with regulators.
• Others, including self-described long-time investors who committed over 100k USD five years ago and now sit on losses above 90%, explicitly state they will not add a single share until the company gets a product approved and generates real revenue. For them, management has “spent” its credibility through years of dilution and delays.

Patient and disease-focused communities

In RRP-focused patient forums, the tone is very different: discussions tend to be detailed and pragmatic, centred on surgery burden, quality of life and the prospect of an injectable treatment that might allow patients to go months or years without going back to the operating room. Here, the company’s messaging around “every surgery matters” resonates strongly and the main concern is access and timing rather than stock price.

Important: all comments from Reddit, Stocktwits, forums and similar platforms come from non-professional traders or patients. They can be useful to gauge sentiment but they are not a reliable source of financial, medical or regulatory advice.

Analyst expectations and scenario map

Consensus view

According to recent consensus compilations, nine covering analysts currently classify INO as a “Hold” on average, with one Sell, three Hold and five Buy ratings, and an average 12-month price target around 9 USD. Individual targets span a wide range (roughly 3–18 USD), reflecting very different assumptions about probability of approval, revenue ramp and capital structure evolution.

Independent aggregators that look at a slightly different analyst set report a similar picture: median targets in the high-single-digits, with upside of several hundred percent relative to late-December 2025 spot prices, but explicitly framed as high-risk, binary-outcome exposure.

Very high-level scenario sketch (editorial, not valuation)

• Positive regulatory outcome, survivable dilution INO-3107 is approved in RRP, whether under accelerated or traditional approval, and Inovio manages to bridge the gap to launch with a mix of equity and non-dilutive funding that does not completely crush the cap table. In this world, INO behaves like a traditional rare-disease commercialisation story with potential upside from label expansion and ex-US rights.
• Regulatory delay or messy negotiation FDA pushes for additional data, a stricter endpoint or a different analysis, delaying or complicating approval. With cash runway into 2Q 2026 and PDUFA in Q4 2026, this scenario almost automatically implies more heavy dilution, and sentiment could deteriorate sharply even before a final decision.
• Regulatory failure A clear rejection or a requirement for a new, large trial without a credible funding path could effectively collapse the current equity story, leaving early-stage assets (INO-3112, INO-5401, DMAb) as scientific, but not near-term commercial, optionality.

None of these sketches is a forecast or probability assignment. They are simple frames to highlight how much of the current analyst upside is contingent on a narrow set of regulatory and financing assumptions.

Key risks and editorial bottom line

Key risks

• Single-asset concentration – near-term equity value is overwhelmingly tied to INO-3107; other pipeline assets are too early or too small to materially de-risk the story on their own.
• Regulatory uncertainty around accelerated approval – the FDA has already flagged concerns about eligibility; details of the discussion will matter, and a Standard Review timetable does not guarantee a positive outcome.
• Funding gap vs PDUFA – current cash does not clearly cover the period up to and beyond the October 2026 PDUFA. Additional financing – likely equity or equity-linked – looks probable, with dilution risk for existing shareholders.
• Execution risk in a rare disease market – even with approval, commercial execution in a small, specialised market (ENT centres, tertiary hospitals, Europe/UK alignment) is non-trivial and will require investment in a lean but competent field infrastructure.
• Reputational overhang with retail – years of heavy dilution and missed timelines mean that parts of the retail base have effectively written off management’s credibility; this can exacerbate volatility and limit the “story stock” premium even if data are good.

Bottom line (editorial, educational only)

The INO equity story is simple and harsh at the same time: a small company with a potentially important DNA medicine for a rare but very real disease burden, but with a long history of dilution and a funding runway that stops before the key regulatory date.

Clinically, the surgery-reduction data in RRP, plus the durability now supported by The Laryngoscope paper, make INO-3107 a serious candidate to become the first non-surgical standard in this niche if approved. Regulators, however, do not approve “mechanistic plausibility plus nice graphs”; they approve drugs when they are convinced that the totality of evidence supports safety and efficacy under the chosen framework, and the latest FDA letter shows that the debate on that framework is still open.

For traders and investors, this remains a high-beta, binary-outcome name where risk management, position sizing and time horizon may matter more than the raw upside scenarios advertised in many retail posts. The market clearly understands the binary nature of the story – as seen by the violent move on 29 December – but opinions differ widely on whether the current price compensates for that risk.

This entire section is an editorial synthesis meant for educational purposes and discussion. It is not, and must not be interpreted as, a recommendation to buy, hold or sell INO or any other security.